China’s rise in biotech to potentially lower healthcare costs, life science investor says

China’s rise in creating biotechnology to the world provides a possible alternative to expensive health care products from Western suppliers, but geopolitical tensions are still a major challenge to globalization efforts in the country, according to a local investor in this sector.

“We can reduce the cost of health care and benefit from more people through technological innovation and improve efficiency,” said Da Liu, the administrative director of the CR-CP Fund, said in an interview with The Post earlier this week. “China’s recent achievements in biotechnology show that it is possible.”

The CR-CP Life Science Fund was launched in 2019 by the state-run China Resources collection and the Charoen Pokphand Group, with $ 170 million under management. The companies supported by the Legend Biotech box, which was published in New York in 2020, and based in Singapore, which included their shares in Hong Kong in May this year.

Do you have questions about the largest topics and trends from all over the world? Get the answers using the knowledge SCMP knowledge, our new platform for coordinated content with supervisors, common questions, analyzes, and graphs that our award -winning team brought to you.

Innovative drugs that come out of biotechnology companies in China have become an increasingly popular license targets among multinational companies (MNCS) in recent years, which has led to what some call the “Deepseek” for the local industry.

Da Leo, Managing Director of the CR-CRP Fund. Photo: Alt = Da Liu, Managing Director of the CR-CP Life Science Fund. Photo: Bulletin>

The US investment Bank said in a report last month that multinationals have turned their attention to Chinese technology and biotechnology companies because of “cost efficiency, accelerating time and promising quality.”

Among the top 10 global drug deals according to the volume of transactions in the first half of the year, seven licenses from Chinese companies participated, according to a report issued in July.

However, China was still in the early stages of innovative life sciences, and local companies faced a “torture forward” to become international leaders, as Liu wrote in his book, Life Sciences: from an investment perspective in China, Posted in 2023.

“China will not be able to produce [biopharmaceutical] MNCS l [another] Liu said on Tuesday.

MNCS is mostly Western MNCS through integration and acquisitions, and benefits from increasing globalization in recent decades, according to LIU. He said that the current geopolitical environment hindered the border integration efforts for Chinese companies.